
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna demonstrates a robust financial trajectory, projecting product sales growth from $1.73 billion in 2025 to $2.15 billion in 2026, signifying its expanding market presence and operational capabilities. The recent $1.5 billion debt deal enhances the company's balance sheet and provides increased flexibility to navigate uncertainties while pursuing future opportunities, further underpinning its financial stability. Additionally, improvements in manufacturing efficiency are expected to re-expand gross margins, which have rebounded from a low of 30% in 2023 back to 50% in 2025, reflecting effective management and a strong recovery in profitability.
Bears say
Moderna's financial outlook has weakened significantly due to declining COVID vaccine sales, which dropped to $6.7 billion in 2023 from $18 billion in 2022, leading to reduced revenue guidance for 2025. The company's growth potential is further constrained by competitive pressures in the RSV vaccine market and slow progress in its broader pipeline beyond respiratory vaccines. As a result of these challenges, the valuation for COVID-related vaccines has also been revised downward from $11.70 billion to $10.50 billion, reflecting the decreasing importance of COVID sales amidst a transitioning pandemic landscape.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares